Enliven Therapeutics: director Garland J. Scott disposes of $606,719 in common shares

Director Garland J. Scott exercised stock options for 13,000 Enliven Therapeutics common shares on Oct. 1, 2026 at USD 15.47 and sold them the same day at a weighted average price of USD 46.6707. His directly held common stock position fell to 0 shares following the transactions.